NATX Plasmids, for: DNA Vaccines, Gene Therapeutics, Viral Vectors andBiophamacueticals

DNA Vaccines: Rapid Development and Rapid Deployment
Providing vaccines in a pandemic timeframe

NTC PRODUCTS AND SERVICES


VECTORS
X
Mammalian Vectors
XAntibiotic-Free Vecotrs
XRig-I Activating Vectors
XpDNAVACCUltra Vector
XLinear Vectors
XRecombineering Vectors
XAutolytic E. coli Cell Lines
XGene Sllencing (transient)
XGene Sllencing (retroviral, stable)
XAnti-Silencing Elements

CELL LINES
XAutolytic E. coli Cell Lines

DNA VACCINES
XXX
DNA Vaccine References
XXX
Pricing
XXXX
PRECISION CLONING
XX
Services and Pricing

RECOMBINANT PROTEINS
X
pVEX™
X
Fluorescent Proteins

PLASMIDS
XSmall Scale Plasmid DNA
XSmall Scale C of A
XLarge Scale Plasmid DNA
XLarge Scale C of A
XPlasmid DNA Order Form
XE. coli Cell paste
XPlasmid Detox Service, NEW!
X
DNA FERMENTATION PROCESS
X
HyperGRO™ Process
X
HyperGRO™ Licensing
X
HyperGRO™ Pricing

PROCESS DEVELOPMENT
X
Process Development Basics
X
Process Licensing

HYPERTAQ™ DNA POLYMERASE


NTC Contacts:

Email: support@natx.com
Phone: (402) 472-6530
Fax: (402) 472-6532

site map | home | contact us



NTC's new (2010), rapidly deployable set of DNA vaccination tools can be readily adapted to any antigens in a two-week, "precision cloning" turnaround service.

NTC's leading vector system offers the following improvments in DNA backbone architecture:

1.
Reduced genome (only essential sequences: increases potency, decreases recombination potential)
2.
Trafficking (DNA to the nucleus, protein to selected presentation pathways)
3.
Optimized expression via transcriptional and translational enhancement and a synthetic intron
4.
Antibiotic free (meets regulatory demands)
5.
Selected co-stimulators (activates antigen presentation, prevents tolerization)
6.
Highest yield in the fermentor (increases purity, cost effectiveness)

XXNTC Vector Advantages

• DNA Vaccination

• Therapeutic Vector

• Native Expression

• Secreted (TPA tag)

• Minimal Backbone

• Reporter (EGFP)

• Regulatory Compliance

• Simultaneous Cloning


Plus, choose from the following special advantages included on the Vector Selection Flowchart below.
A typical advanced NTC vector, NTC8685-EGFP, with the following features: markerless (sucrose selection), enhanced transcription (SV40/CMV), enhanced translation (CMV/HTLV-1-R), enhanced translation (VA1), enhanced plasmid production (PAS-BH).
A typical advanced NTC vector, NTC8685-EGFP, with the following features: markerless (sucrose selection), enhanced transcription (SV40/CMV), enhanced translation (CMV/HTLV-1-R), enhanced translation (VA1), enhanced plasmid production (PAS-BH).

XXVector Selection Flowchart

Selection
Transgene Targeting
HTLV-I R transient expression enhancer
VA1 transient expression enhancer
SV40-PAS-BH increased plasmid yield  backbone
RIG-I activating backbone
Vector
Kan Secreted; GPI anchored; Proteosome; Endosome; or  Native
No
No
No
No
pDNAVACCUltra
Sucrose
Secreted; or Native
Yes
No
No
No
NTC8382
NTC8385
Sucrose Secreted; or Native
Yes
Yes
No
No
NTC8382-VA1
NTC8385-VA1
Kan Secreted; or Native
Yes
No
*Yes
No
NTC7482
NTC7485
Kan Secreted; or Native
Yes
Yes
*Yes
Yes
NTC7482-eRNA41H
NTC7485-eRNA41H
Sucrose Secreted; or Native
Yes
No
*Yes
No
NTC8482
NTC8485
Sucrose Secreted; or Native
Yes
Yes
*Yes
Yes
NTC8482-eRNA41H
NTC8485-eRNA41H
Sucrose Secreted; or Native
Yes
Yes
*Yes
No
NTC8682
NTC8685

*Save 20% off large scale production cost with NTC’s high-yield, SV40-PAS-BH vectors!
(for a limited time)


XXCompare NTC's vectors with our competitors


EGFP transgene expression (fluorescence) in human HEK293 cell line after transfection of dcm+ or dcm- NTC8685, gWIZ and pVAX1 CMV promoter plasmid vectors.


Figure 1: EGFP transgene expression (fluorescence) in human HEK293 cell line after transfection of dcm+ or
dcm- NTC8685, gWIZ and pVAX1 CMV promoter plasmid vectors.



Figure 2: NTC8385-VA1 expression compared to gWIZ-EGFP and pVAX1-EGFP in HEK293 cells.

Figure 2: NTC8385-VA1 expression compared to gWIZ-EGFP and pVAX1-EGFP in HEK293 cells.



XXDNA Vaccine References

Protection against anthrax and plague (NMRC/Porton Down/NTC), John Palmer et al., Abstract Biodefense Nov 07 31 07 (2) (3).

pDNAVACCUltra rabies DNA vaccine targeting.pdf, Kaur et al.

GPI anchored anthrax vaccine.pdf, Midha and Bhatnagar

Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune.pdf, Midha and Bhatnagar

NTC eRNA DNA Vaccines. Coexpressed RIG-I agonist enhances antigen-specific immune response to Influenza DNA Vaccine, James Williams Ph.D., Jeremy Luke, B.A., and Clague Hodgson Ph.D.

pDNAVACCUltra Vector family: high throughput intracellular targeting, 2006. James Williams, Jeremy Luke, Lance Johnson and Clague Hodgson


Contact NTC, Toll free: 1-(888) WIZ-BANG

Plasmids, Recombinant Proteins, DNA Vaccines, Viral Vectors, Therapeutic Genes, Fermentation Technology for Gene Therapy and Biotechnology
NTC's free resource "Site" for the biotechnology industry,
including Databases and Sequences Analysis Tool
s



WWW http://www.natx.com